Findings

What do systematic reviews say?

23 questions · 23 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 17.4%GRADE not reported 0 · 0%Very low 11 · 47.8%Low 6 · 26.1%Moderate 2 · 8.7%High 0 · 0%

Low molecular weight heparin vs no LMWH

Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) showed no clear difference in minor bleeding (up to 3 months) compared with no LMWH (low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 1.35 [0.62, 2.92]
2 studies · 544 participants
Low

Low molecular weight heparin vs no LMWH

Antibiotic versus heparin only lock/flush solution: catheter‐related infections · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) showed no clear difference in catheter‐related infection (up to 3 months) compared with no LMWH (low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 0.97 [0.52, 1.79]
2 studies · 474 participants
Low

Low molecular weight heparin vs no LMWH

Thrombocytopenia · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) showed no clear difference in thrombocytopenia (up to 3 months) compared with no LMWH (low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 1.03 [0.8, 1.33]
4 studies · 1002 participants
Low